A phase 1 clinical trial reports that local injection of anti-CTLA-4 in patients with early-stage melanoma reduced immune-related adverse events associated with systemic delivery of this immune checkpoint blockade therapy. @amsterdamumc https://t.co/8RdEP1GYAI